Endocrine Abstracts

Background: Immune checkpoint inhibitors (ICIs) constitutes a novel treatment for patients with melanoma. Endocrine-related adverse effects are now a distinctive clinical entity of ICIs, with hypophysitis and thyroiditis being the most common. Recent consensus doesn’t suggest routinely screening of bone mass indexes in patients on ICIs since data in the literature are scarce.Methods: Data regarding bone disease were retrospectively analysed in 118 p...

Background: Immune checkpoint inhibitors (ICIs) (anti-CTLA-4, PD-1 inhibitors, PD-L1 inhibitors) are considered a widely used therapeutic choice for several cancer types. However ICI therapy is frequently complicated by adverse events; endocrine toxicities are the most common ones.Methods: To assess in a retrospective observational study in a tertiary hospital the incidence and the characteristics of the immunotherapy-related endocrine adverse events (ir...

Background: The use of immune checkpoint inhibitors (ICIs) has been lately established as a promising and effective treatment in several solid malignancies. Endocrine-related adverse effects are common, however their effects on bone metabolism is unknown.Methods: We retrospectively investigated the prevalence of bone-related complications in patients undergoing or completing treatment with ICIs. Epidemiological and clinical data from the medical files of...